Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)

Market Cap	48.08B +471.7%
Revenue (ttm)	1.70B +42.7%
Net Income	366.30M +177.0%
EPS	0.86 +171.8%
Shares Out	n/a
PE Ratio	131.25
Forward PE	149.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,196,941
Open	120.93
Previous Close	120.51
Day's Range	119.20 - 128.77
52-Week Range	48.06 - 154.99
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHA:688796

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 1,922
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688796

Financial Performance

In 2025, SHA:688796's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 16, 2026

Data Sources Report a data error